None listed
Conditions
Brief summary
This study investigates the safety and effectiveness of Dapagliflozin, a medication typically used for diabetes, in non-diabetic patients who have had a heart attack (acute myocardial infarction). The aim is to determine whether Dapagliflozin can improve heart function and reduce complications in this patient group. Participants will receive standard treatment, with or without Dapagliflozin, and will be followed for one year. We hypothesise that Dapagliflozin will lead to better recovery outcomes even in non-diabetic patients..
Interventions
This interventional study evaluates the effects of Dapagliflozin in non-diabetic patients with primary anterior ST-elevation myocardial infarction (STEMI).
Intervention Group (Dapa group): Patients receive Dapagliflozin 10 mg once daily, administered as an oral tablet, initiated within the first 48 hours of hospital admission. The intervention is continued for one year. Adherence is monitored through regular follow-up visits. To evaluate the effects of the intervention, echocardiographic assessm
This interventional study evaluates the effects of Dapagliflozin in non-diabetic patients with primary anterior ST-elevation myocardial infarction (STEMI). Intervention Group (Dapa group): Patients receive Dapagliflozin 10 mg once daily, administered as an oral tablet, initiated within the first 48 hours of hospital admission. The intervention is continued for one year. Adherence is monitored through regular follow-up visits. To evaluate the effects of the intervention, echocardiographic assessments and NT-proBNP measurements are conducted at baseline and at the end of the one-year follow-up period.
Sponsors
Erebouni Medical Center
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Age: Adults between 18 and 80 years old, inclusive Diagnosis: Confirmed primary anterior ST-elevation myocardial infarction (STEMI) Time Frame: Symptom onset within 24 hours before hospital admission Intervention Timing: Underwent primary percutaneous coronary intervention (PCI) Left Ventricular Function: Left ventricular ejection fraction of 45% or less Biomarker Criteria: NT-proBNP concentration greater than 900 pg/ml at admission Diabetes Status: No history of diabetes mellitus (Non-diabetic patients only)
Exclusion criteria
Cardiogenic shock History of diabetes mellitus (to ensure study only includes non-diabetic patients)
Outcome results
None listed